Large alterations in ganglioside and neutral glycosphingolipid patterns in brains from cases with infantile neuronal ceroid lipofuscinosis/polyunsaturated fatty acid lipidosis.
Lipid composition was studied on cerebral tissue from nine children who had died of a progressive encephalopathy called the infantile form of neuronal ceroid lipofuscinosis (INCL) or polyunsaturated fatty acid lipidosis (PFAL). In the terminal stage of the disease, the concentrations of all lipid classes were found to be significantly reduced in the cerebral and cerebellar cortex and white matter. The concentration of gangliosides of the cerebral cortex was 15% and that of cerebrosides (galactosylceramide) in white matter 0.2-5% of the normal values for the children's ages. The reduction of gangliosides mainly affected those of the gangliotetraose series, particularly GD1a. The fatty acids of the linolenic acid series were strongly reduced in ethanolamine and serine phosphoglycerides. A very large increase up to 100-fold of oligoglycosphingolipids of the globo series and two fucose-containing lipids of the neolacto series was found in the forebrain of the three advanced cases examined. The brain tissue also contained very high concentrations of mono-, di-, and trisialogangliosides of the lacto and neolacto series, gangliosides with type 1 chain dominating. The structures of the gangliosides were tentatively identified by gas chromatography-mass spectrometry and monoclonal antibodies with carefully determined epitope specificity. The gangliosides and neutral glycosphingolipids had very similar fatty acid composition, consisting of about 40% stearic acid and 40% C24-acids.
Svennerholm
L
L
Department of Psychiatry and Neurochemistry, Göteborg University, St. Jörgen's Hospital, Hisings Backa, Sweden.
Fredman
P
P
Jungbjer
B
B
Månsson
J E
JE
Rynmark
B M
BM
Boström
K
K
Hagberg
B
B
Norén
L
L
Santavuori
P
P
D001921:Brain / Q000378:metabolism*; D002525:Cerebellar Cortex / Q000378:metabolism; D002540:Cerebral Cortex / Q000378:metabolism; D002648:Child; D005227:Fatty Acids / Q000378:metabolism; D005231:Fatty Acids, Unsaturated / Q000378:metabolism*; D005699:Galactosylceramides / Q000378:metabolism; D005732:Gangliosides / Q000378:metabolism*; D008401:Gas Chromatography-Mass Spectrometry; D005915:Globosides / Q000378:metabolism; D006017:Glycolipids / Q000378:metabolism; D006028:Glycosphingolipids / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D008064:Lipidoses / Q000378:metabolism*; D008563:Membrane Lipids / Q000378:metabolism; D009472:Neuronal Ceroid-Lipofuscinoses / Q000378:metabolism*; D014281:Trihexosylceramides
D005227:Fatty Acids; D005231:Fatty Acids, Unsaturated; D005699:Galactosylceramides; D005732:Gangliosides; D005915:Globosides; D006017:Glycolipids; D006028:Glycosphingolipids; D008563:Membrane Lipids; D014281:Trihexosylceramides; C025567:fucolipids; C024032:globotetraosylceramide; C021298:ganglioside, GD1a; C018549:globotriaosylceramide